Author

Elena Marced

Observed names: E Marced, Elena Marced Barrachina, Elena Marced Barrachina

Institution: AbbVie (United States)

Observed institution: AbbVie (United States)

OpenAlex ID: A5052606264

P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease

2023 · J F Colombel, P Irving, et al. · Journal of Crohn s and Colitis · 32

Diferencias en el manejo de la artritis reumatoide precoz y establecida

2011 · Santos Castañeda, Federico Navarro, et al. · Reumatología Clínica · 10

Differences in the management of early and established rheumatoid arthritis

2011 · Santos Castañeda, Federico Navarro, et al. · Reumatología Clínica (English Edition) · 6

Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis

2025 · Walter Reinisch, Edward V Loftus, et al. · Journal of Crohn s and Colitis · 4

947 Efficacy and Safety of Upadacitinib for the Treatment of Fistulas and Fissures in Patients With Crohn's Disease

2023 · Jean Frederic Colombel, Peter M. Irving, et al. · Gastroenterology · 2

Tu1705 DELAYED CLINICAL RESPONSE IN PATIENTS WITH CROHN'S DISEASE RECEIVING UPADACITINIB THERAPY

2023 · Geert D'Haens, Jakob B. Seidelin, et al. · Gastroenterology · 2

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

2026 · Shu Chen Wei, Hiroshi Nakase, et al. · Journal of Gastroenterology and Hepatology · 1

S1984 Efficacy of Retreatment With Upadacitinib After Treatment Interruption in Ulcerative Colitis: Data From the U-ACTIVATE Open-Label Extension

2025 · Remo Panaccione, Jean-Frederic Colombel, et al. · The American Journal of Gastroenterology · 1

P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies

2023 · S Vermeire, S Danese, et al. · Journal of Crohn s and Colitis · 1

Trends in Corticosteroid Use and Excess in Patients With Inflammatory Bowel Disease in the United States, Sweden, and Denmark

2026 · Tim Raine, Gil Y. Melmed, et al. · JCC Plus

Efficacy of Upadacitinib Retreatment or Dose Escalation After Loss of Response in Ulcerative Colitis: Data From the Open-Label Extension of the U-ACTIVATE Study

2026 · Remo Panaccione, Jean-Frédéric Colombel, et al. · Gastro Hep Advances

Su1773 ACHIEVEMENT OF CLINICAL AND ENDOSCOPIC OUTCOMES BY BASELINE CORTICOSTEROID USE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RECEIVED RISANKIZUMAB INDUCTION TREATMENT: A POST-HOC ANALYSIS OF THE INSPIRE STUDY

2024 · Peter Bossuyt, Edouard Louis, et al. · Gastroenterology

Tu1721 EFFECT OF UPADACITINIB ON INFLAMMATORY MARKERS AND CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE IN THE PHASE 3, U-EXCEL, U-EXCEED, AND U-ENDURE STUDIES

2023 · Séverine Vermeire, Silvio Danese, et al. · Gastroenterology

Works count: 13

Citation count: 59

H-index: 4

I10-index: 2